
Myovant Sciences (NASDAQ:MYOV) and Pfizer (NASDAQ:PFE) received U.S. Food and Drug Administration (FDA) acceptance of its supplemental New Drug Application (sNDA) review for its lead drug candidate MYFEMBREE for the treatment of patients with heavy menstrual bleeding associated with uterine fibroids.
The regulatory agency has assigned Standard Review for the application and set a PDUFA target action date of Jan. 29, 2023.